XCSFDHG46767FHJHJF
tdp2664 Epic Stock Picks Shares of Valeant Pharmaceuticals Int (USA) (NYSE:VRX) inched up in the off trading hours after the massive sell-off of the company's stock. The company on Thursday stated that its 2 nd quarter earnings went up by 66 % as its revenue went up after its purchase by Biovail Corp. last September. The company shares went down by 22 % to close at $40.85. The company earned $56.4 million, or 17 cents per share, during the quarter end on 30 th June in comparison to the net income totaling to $34 million, or 21 cents per share earned in the previous year. the Adjusted earning of the company were 73 cents per share, and its revenue doubled to $609.4 million. According to FactSet Analysts expected an average earnings of 65 cents per share on $604.5 million in revenue. The company now expects an earning of $2.70 to $3 per share this year, more from the forecasted earning of $2.65 to $2.90 in the previous year however Analysts expected an average earnings of $2.78 per share. The company dealt with generic drugs and treatments for chronic illnesses. Biovail’s products included the anti-depressant Wellbutrin, the pain drug Ultram ER and Zovirax, a treatment for herpes cold sores. The company's shares went up by 14 cents to $40.99 in the electronic trading.
No comments:
Post a Comment